Use of antisense oligonucleotide technology to investigate signaling pathways in megakaryocytes.
Avraham
Hava
H
Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Bostron, MA, USA.
Avraham
Shalom
S
Zagozdzon
Radoslaw
R
D015536:Down-Regulation; D020868:Gene Silencing; D006801:Humans; D008533:Megakaryocytes / Q000187:drug effects* / Q000378:metabolism*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*
D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering; D011505:Protein-Tyrosine Kinases; C085377:MATK protein, human; D016392:Proto-Oncogene Proteins pp60(c-src)